欧洲药品管理局-话题@MedSci

#欧洲药品管理局#

58篇内容 | 2451人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1425444, encodeId=9024142544498, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请, objectType=article, longId=167495, objectId=7c2016e4958b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c2016e4958b, replyNumber=0, likeNumber=0, createdTime=2019-06-03, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c2016e4958b, moduleTitle=欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c2016e4958b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425443, encodeId=89d1142544323, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局（EMA）推荐4种药物获批：抗真菌感染、化疗保护和威尔森氏病药物, objectType=article, longId=167494, objectId=f17c16e4943f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f17c16e4943f, replyNumber=0, likeNumber=68, createdTime=2019-06-03, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f17c16e4943f, moduleTitle=欧洲药品管理局（EMA）推荐4种药物获批：抗真菌感染、化疗保护和威尔森氏病药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f17c16e4943f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425442, encodeId=b2eb1425442c0, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=由于毒副作用，欧洲药品管理局建议限制Lemtrada在多发性硬化症中的使用, objectType=article, longId=164344, objectId=ad231643441f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad231643441f, replyNumber=0, likeNumber=89, createdTime=2019-04-17, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad231643441f, moduleTitle=由于毒副作用，欧洲药品管理局建议限制Lemtrada在多发性硬化症中的使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad231643441f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425441, encodeId=783f142544141, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局批准了Diurnal的皮质醇替代品Chronocort的监管路径，治疗先天性肾上腺增生, objectType=article, longId=164169, objectId=65ad16416963, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65ad16416963, replyNumber=0, likeNumber=68, createdTime=2019-04-14, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65ad16416963, moduleTitle=欧洲药品管理局批准了Diurnal的皮质醇替代品Chronocort的监管路径，治疗先天性肾上腺增生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65ad16416963)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425440, encodeId=fec114254403d, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, objectType=article, longId=161940, objectId=45871619401a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45871619401a, replyNumber=0, likeNumber=97, createdTime=2019-03-10, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45871619401a, moduleTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45871619401a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425439, encodeId=22d8142543932, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局的人类药物委员会（CHMP）推荐八种新药, objectType=article, longId=161661, objectId=d190161661ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d190161661ad, replyNumber=0, likeNumber=82, createdTime=2019-03-06, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d190161661ad, moduleTitle=欧洲药品管理局的人类药物委员会（CHMP）推荐八种新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d190161661ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425438, encodeId=912c14254389e, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=Hansa Biopharma宣布欧洲药品管理局接受IDEFIRIX（imlifidase）用于高度敏感的肾移植患者的营销授权申请, objectType=article, longId=161543, objectId=416d16154305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=416d16154305, replyNumber=0, likeNumber=77, createdTime=2019-03-04, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=416d16154305, moduleTitle=Hansa Biopharma宣布欧洲药品管理局接受IDEFIRIX（imlifidase）用于高度敏感的肾移植患者的营销授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=416d16154305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425437, encodeId=aaff142543e02, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局将规范基因和细胞疗法发布临床试验指南草案, objectType=article, longId=161129, objectId=9789161129cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9789161129cc, replyNumber=0, likeNumber=71, createdTime=2019-02-27, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9789161129cc, moduleTitle=欧洲药品管理局将规范基因和细胞疗法发布临床试验指南草案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9789161129cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425436, encodeId=544914254368d, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局在英国脱欧前搬离伦敦, objectType=article, longId=159136, objectId=4cde159136d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cde159136d8, replyNumber=0, likeNumber=67, createdTime=2019-01-30, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cde159136d8, moduleTitle=欧洲药品管理局在英国脱欧前搬离伦敦, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cde159136d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425435, encodeId=34001425435d3, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=Zepsyre（lurbinectedin）在小细胞肺癌治疗中获欧洲药品管理局孤儿药认定, objectType=article, longId=158995, objectId=d85315899529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d85315899529, replyNumber=0, likeNumber=72, createdTime=2019-01-28, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d85315899529, moduleTitle=Zepsyre（lurbinectedin）在小细胞肺癌治疗中获欧洲药品管理局孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d85315899529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425434, encodeId=ecdb14254342a, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局人用药品委员会向欧盟推荐13种药物用于上市, objectType=article, longId=149596, objectId=39d4149596de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39d4149596de, replyNumber=0, likeNumber=61, createdTime=2018-09-27, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39d4149596de, moduleTitle=欧洲药品管理局人用药品委员会向欧盟推荐13种药物用于上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39d4149596de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425433, encodeId=3323142543361, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局授予罗氏RG6042为优先药物用于治疗亨廷顿舞蹈症, objectType=article, longId=145827, objectId=80e814582ef0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e814582ef0, replyNumber=0, likeNumber=0, createdTime=2018-08-05, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e814582ef0, moduleTitle=欧洲药品管理局授予罗氏RG6042为优先药物用于治疗亨廷顿舞蹈症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e814582ef0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425432, encodeId=8acb14254322d, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局已经接受了Tagrisso（osimertinib）营销授权申请, objectType=article, longId=122074, objectId=1ca11220e4f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ca11220e4f0, replyNumber=0, likeNumber=80, createdTime=2017-12-03, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ca11220e4f0, moduleTitle=欧洲药品管理局已经接受了Tagrisso（osimertinib）营销授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ca11220e4f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425431, encodeId=841e14254312a, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=峰回路转！吉利德重磅抗癌药Zydelig通过欧洲药品管理局安全审查！, objectType=article, longId=72753, objectId=f303e27534d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f303e27534d, replyNumber=0, likeNumber=71, createdTime=2016-07-15, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f303e27534d, moduleTitle=峰回路转！吉利德重磅抗癌药Zydelig通过欧洲药品管理局安全审查！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f303e27534d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425430, encodeId=d8251425430ce, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局（EMA）批准疟疾疫苗Mosquirix（RTS;S）上市, objectType=article, longId=53815, objectId=e50a538151f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e50a538151f, replyNumber=0, likeNumber=124, createdTime=2015-07-28, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e50a538151f, moduleTitle=欧洲药品管理局（EMA）批准疟疾疫苗Mosquirix（RTS;S）上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e50a538151f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425429, encodeId=3d5a14254296a, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局启动HPV疫苗安全性调查, objectType=article, longId=53408, objectId=8d1a534082e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d1a534082e, replyNumber=0, likeNumber=106, createdTime=2015-07-17, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d1a534082e, moduleTitle=欧洲药品管理局启动HPV疫苗安全性调查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d1a534082e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425428, encodeId=239e1425428ca, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局建议限制甲氧氯普胺的使用, objectType=article, longId=24742, objectId=360724e429b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=360724e429b, replyNumber=0, likeNumber=74, createdTime=2013-09-24, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=360724e429b, moduleTitle=欧洲药品管理局建议限制甲氧氯普胺的使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=360724e429b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1425427, encodeId=a7f3142542e24, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, objectTitle=欧洲药品管理局开始审查芬戈莫德, objectType=article, longId=3802, objectId=fae6380276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fae6380276, replyNumber=0, likeNumber=60, createdTime=2012-02-05, rootId=0, userName=isabellayj, userId=c44f3972955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fae6380276, moduleTitle=欧洲药品管理局开始审查芬戈莫德, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fae6380276)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

欧洲药品管理局

2020-05-29

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请

2019-06-03

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局（EMA）推荐4种药物获批：抗真菌感染、化疗保护和威尔森氏病药物

2019-06-03

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

由于毒副作用，欧洲药品管理局建议限制Lemtrada在多发性硬化症中的使用

2019-04-17

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局批准了Diurnal的皮质醇替代品Chronocort的监管路径，治疗先天性肾上腺增生

2019-04-14

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效

2019-03-10

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局的人类药物委员会（CHMP）推荐八种新药

2019-03-06

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

Hansa Biopharma宣布欧洲药品管理局接受IDEFIRIX（imlifidase）用于高度敏感的肾移植患者的营销授权申请

2019-03-04

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局将规范基因和细胞疗法发布临床试验指南草案

2019-02-27

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局在英国脱欧前搬离伦敦

2019-01-30

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

Zepsyre（lurbinectedin）在小细胞肺癌治疗中获欧洲药品管理局孤儿药认定

2019-01-28

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局人用药品委员会向欧盟推荐13种药物用于上市

2018-09-27

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局授予罗氏RG6042为优先药物用于治疗亨廷顿舞蹈症

2018-08-05

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局已经接受了Tagrisso（osimertinib）营销授权申请

2017-12-03

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

峰回路转！吉利德重磅抗癌药Zydelig通过欧洲药品管理局安全审查！

2016-07-15

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局（EMA）批准疟疾疫苗Mosquirix（RTS;S）上市

2015-07-28

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局启动HPV疫苗安全性调查

2015-07-17

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局建议限制甲氧氯普胺的使用

2013-09-24

isabellayj (审核中...)

前往app查看评论内容

#欧洲药品管理局#

欧洲药品管理局开始审查芬戈莫德

2012-02-05

科室
- - 订阅+
  - 更多科室
工具
服务